{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T22:05:12Z","timestamp":1759615512913},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s40261-012-0002-8","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T23:08:52Z","timestamp":1355958532000},"page":"735-745","source":"Crossref","is-referenced-by-count":7,"title":["A 6-Week, Randomized, Multicentre, Open-Label Study Comparing Efficacy and Tolerability of Amisulpride at a Starting Dose of 400\u00a0mg\/day versus 800\u00a0mg\/day in Patients with Acute Exacerbations of Schizophrenia"],"prefix":"10.1007","volume":"32","author":[{"given":"Seung Jae","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bon Hoon","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"issue":"13","key":"2_CR1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/00023210-200418130-00007","volume":"18","author":"K McKeage","year":"2004","unstructured":"McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18(13):933\u201356.","journal-title":"CNS Drugs"},{"issue":"4","key":"2_CR2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050361","volume":"132","author":"HJ Moller","year":"1997","unstructured":"Moller HJ, Boyer P, Fleurot O, et al. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl). 1997;132(4):396\u2013401.","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"2_CR3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","volume":"98","author":"A Puech","year":"1998","unstructured":"Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand. 1998;98(1):65\u201372.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002130050614","volume":"137","author":"H Wetzel","year":"1998","unstructured":"Wetzel H, Gr\u00fcnder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology: a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-\/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl). 1998;137(3):223\u201332.","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"2_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-200403000-00002","volume":"19","author":"A Mortimer","year":"2004","unstructured":"Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6\u00a0months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19(2):63\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2_CR6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","volume":"88","author":"J Peuskens","year":"1999","unstructured":"Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 1999;88(2):107\u201317.","journal-title":"Psychiatry Res"},{"issue":"9618","key":"2_CR7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085\u201397.","journal-title":"Lancet"},{"issue":"1","key":"2_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/tcrm.2007.3.1.3","volume":"3","author":"P Nuss","year":"2007","unstructured":"Nuss P, Hummer M, Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clin Risk Manag. 2007;3(1):3\u201311.","journal-title":"Ther Clin Risk Manag"},{"issue":"1\u20132","key":"2_CR9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF02245616","volume":"124","author":"JL Martinot","year":"1996","unstructured":"Martinot JL, Paillere-Martinot ML, Poirier MF, et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology. 1996;124(1\u20132):154\u20138.","journal-title":"Psychopharmacology"},{"issue":"1","key":"2_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177\u201383.","journal-title":"Psychol Med"},{"issue":"1","key":"2_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0165-1781(02)00030-6","volume":"110","author":"O Kampman","year":"2002","unstructured":"Kampman O, Laippala P, Vaananen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002;110(1):39\u201348.","journal-title":"Psychiatry Res"},{"issue":"1","key":"2_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v68n0110","volume":"68","author":"A Karow","year":"2007","unstructured":"Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12\u00a0months of treatment in schizophrenia. J Clin Psychiatry. 2007;68(1):75\u201380.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2005.10.016","volume":"83","author":"DO Perkins","year":"2006","unstructured":"Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53\u201363.","journal-title":"Schizophr Res"},{"key":"2_CR14","volume-title":"Structured clinical interview for DSM-IV Axis I disorders","author":"ME First","year":"1999","unstructured":"First ME, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV Axis I disorders. New York: New York State Psychiatric Institute; 1999."},{"key":"2_CR15","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare; 1976."},{"issue":"2","key":"2_CR16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","volume":"22","author":"D Addington","year":"1993","unstructured":"Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry. 1993;22:39\u201344.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"2_CR18","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft J, Coffey M, et al. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995;166(5):654\u20139.","journal-title":"Br J Psychiatry"},{"issue":"334","key":"2_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"76","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;76(334):1\u2013100.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Anugs JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2_CR21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. Rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"2_CR22","first-page":"401","volume":"45","author":"JH Kim","year":"2006","unstructured":"Kim JH, Min SK, Kim SE, et al. The Korean version of 4th revision of Schizophrenia Quality of Life Scale: validation study and relationship with PANSS. J Korean Neuropsychiatr Assoc. 2006;45(5):401\u201310.","journal-title":"J Korean Neuropsychiatr Assoc"},{"issue":"6","key":"2_CR23","first-page":"480","volume":"16","author":"BH Yoon","year":"2005","unstructured":"Yoon BH, Lee KU, Hong CH, et al. Psychometric properties of Korean version of Drug Attitude Inventory (KDAI-10). Korean J Psychopharmacol. 2005;16(6):480\u20137.","journal-title":"Korean J Psychopharmacol"},{"issue":"6","key":"2_CR24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0893-133X(02)00375-5","volume":"27","author":"D Sechter","year":"2002","unstructured":"Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27(6):1071\u201381.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"2_CR25","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.pnpbp.2007.07.005","volume":"31","author":"SW Kim","year":"2007","unstructured":"Kim SW, Shin IS, Kim JM, et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1504\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"2_CR26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eurpsy.2006.09.003","volume":"21","author":"JM Vanelle","year":"2006","unstructured":"Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2\u00a0months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 2006;21(8):523\u201330.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"2_CR27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","volume":"159","author":"S Leucht","year":"2002","unstructured":"Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159(2):180\u201390.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00004850-200507000-00001","volume":"20","author":"H Lublin","year":"2005","unstructured":"Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol. 2005;20(4):183\u201398.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u20132","key":"2_CR29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00213-003-1721-6","volume":"173","author":"S Leucht","year":"2004","unstructured":"Leucht S, Wagenpfeil S, Hamann J, et al. Amisulpride is an \u201catypical\u201d antipsychotic associated with low weight gain. Psychopharmacology. 2004;173(1\u20132):112\u20135.","journal-title":"Psychopharmacology"},{"issue":"4","key":"2_CR30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004850-199907000-00002","volume":"14","author":"C Coulouvrat","year":"1999","unstructured":"Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14(4):209\u201318.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-0031-1291175","volume":"45","author":"EY Kim","year":"2012","unstructured":"Kim EY, Kim SH, Lee NY, et al. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry. 2012;45(2):57\u201363.","journal-title":"Pharmacopsychiatry"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0002-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0002-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0002-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T08:08:05Z","timestamp":1562486885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0002-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0002-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]}}}